Given the state of political affairs currently engulfing health care, our industry regularly gets vilified and is frequently a victim of misperception.
Dan Steiber, RPh, Specialty Pharmacy Times® Editor-In-Chief & Executive Vice President
Advertisement
Articles by Dan Steiber, RPh, Specialty Pharmacy Times® Editor-In-Chief & Executive Vice President
The meteoric rise in drug spending over the past 10 years has been driven by specialty therapeutics, while spending on traditional therapies has decreased.
Advertisement
Latest Updated Articles
Patients First: Is Specialty Pharmacy in the Blueprint?Published: July 18th 2018 | Updated:
Community “Specialty†Pharmacy vs the CompetitionPublished: September 10th 2018 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
GLP-1 Receptor Agonists Show Promise Across Alcohol, Opioid, and Tobacco Use Disorders
2
TACTI-004 Trial Studying Eftilagimod Alfa With Pembrolizumab in Advanced NSCLC to Begin Evaluation
3
UConn’s Medical Writing Certificate Program: It’s Just "Write"
4
Pharmacy Policy Updates for October 2025
5
